Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Paper
  • Published:

RalA requirement for v-Src- and v-Ras-induced tumorigenicity and overproduction of urokinase-type plasminogen activator: involvement of metalloproteases

Abstract

Overproduction of urokinase-type plasminogen activator (uPA) and metalloproteases (MMPs) is strongly correlated with tumorigenicity and with invasive and metastatic phenotypes of human and experimental tumors. We demonstrated previously that overproduction of uPA in tumor cells is mediated by a phospholipase D (PLD)- and protein kinase C-dependent mechanism. The oncogenic stimulus of v-Src and v-Ras results in the activation of PLD, which is dependent upon the monomeric GTPase RalA. We have therefore investigated whether RalA plays a role in uPA and MMP overproduction that is observed in response to oncogenic signals. We report here that NIH3T3 cells transformed by both v-Src and v-Ras, constitutively overproduce uPA and that expression of a dominant negative RalA mutant (S28N) blocks overproduction of uPA in both the v-Src-and v-Ras-transformed cells. v-Src and v-Ras also induced an upregulation of the activity of MMP-2 and MMP-9 as detected by zymograms, however only the v-Src induction correlated with MMP protein levels detected by Western blot analysis. The dominant negative RalA mutant blocked increased MMP-2 and 9 overproduction induced by v-Src, but not the increased activity of MMP-2 and 9 induced by v-Ras. And, consistent with a role for the RalA/PLD pathway in mitogenesis and tumor development, the dominant negative RalA mutant completely blocked tumor formation by v-Src- and v-Ras-transformed NIH3T3 cells injected subcutaneously in syngeneic mice. The data presented here implicate RalA and PLD as signaling mediators for tumor formation and protease production by transformed cells.

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6

Similar content being viewed by others

References

  • Aguirre-Ghiso JA, Alonso DF, Farias EF and Bal de Kier Joffe E. . 1997 Biochim. Biophys. Acta 1356: 171–184.

  • Alonso DF, Farias EF and Bal de Kier Joffe E. . 1993 Cancer Letts. 70: 181–187.

  • Bell SM, Connolly DC, Maihle NJ and Degen JL. . 1993 Mol. Cell. Biol. 13: 5888–5897.

  • Bi K, Roth MG and Ktikstakis NT. . 1997 Curr. Biol. 7: 301–307.

  • Blobe GC, Obeid ML and Hannun YA. . 1994 Cancer Meta. Rev. 13: 411–431.

  • Boyd D. . 1996 Cancer Meta. Rev. 15: 77–89.

  • Burgering BMT and Bos JL. . 1995 TIBS 20: 18–22.

  • Carmeliet P, Moons L, Lijnen R, Baes M, Lemaitre V, Tipping P, Drew A, Eckhout Y, Shapiro S, Lupu F and Collen D. . 1997 Nat. Genet. 17: 439–444.

  • Carpenter CL and Cantley LC. . 1996 Biochim. Biophys. Acta 1288: M11–M16.

  • Exton JH. . 1994 Biochim. Biophys. Acta 1212: 26–42.

  • Exton JH. . 1998 Biochim. Biophys. Acta 1436: 105–115.

  • Foster DA. . 1993 Cell Signalling 5: 389–399.

  • Gum R, Lengyel E, Juarez J, Chen JH, Sieki M and Boyd D. . 1996 J. Biol. Chem. 271: 10672–10680.

  • Gum R, Wang H, Lengyel E, Juarez J and Boyd D. . 1997 Oncogene 14: 1481–1493.

  • Hart IR, Goode NT and Wilson RE. . 1989 Biochim. Biophys. Acta 989: 65–84.

  • Jiang H, Lu Z, Luo JQ, Wolfman A and Foster DA. . 1995a J. Biol. Chem. 270: 6006–6009.

  • Jiang H, Luo J-Q, Urano T, Frankel P, Lu Z, Foster DA and Feig LA. . 1995b Nature 378: 409–412.

  • Lengyel E, Gum R, Stepp E, Juarez J, Wang H and Boyd D. . 1996 J. Cell. Biochem. 61: 430–443.

  • Lengyel E, Wang H, Gum R, Simon C, Wang Y and Boyd D. . 1997 Oncogene 14: 2563–2573.

  • Liotta LA and Stetler-Stevenson WG. . 1991 Cancer Res. 51: 5054–5059.

  • Liotta LA, Steeg PS and Stetler-Stevenson W. . 1991 Cell 64: 327–336.

  • Luo J-Q, Liu X, Frankel P, Rotunda T, Ramos M, Flom J, Jiang H, Feig LA, Morris A, Kahn RA and Foster DA. . 1998 Proc. Natl. Acad. Sci. USA 95: 3632–3637.

  • Luo J-Q, Liu X, Hammond SM, Colley WC, Feig LA, Frohman MA, Morris AJ and Foster DA. . 1997 Biochem. Biophys. Res. Comm. 235: 854–859.

  • Matrisian LM. . 1992 BioEssays 14: 455–463.

  • Mazzieri R, Masiero L, Zanetta L, Monea S, Onisto M, Garbisa S and Mignatti P. . 1997 EMBO J. 16: 2319–2332.

  • Moller LB. . 1993 Blood Coagul. Fibrinol. 4: 293–303.

  • Ossowski L. . 1992 Cancer Res. 52: 6754–6760.

  • Ossowski L and Reich E. . 1983 Cell 35: 611–619.

  • Pittman RN. . 1985 Dev. Biol. 110: 91–101.

  • Qureshi SA, Joseph CK, Gupta R, Hendrickson M, Song J, Bruder J, Rapp U and Foster DA. . 1993 Biochem. Biophys. Res. Comm. 192: 969–975.

  • Reich R, Blumenthal M and Liscovitch M. . 1995 Clin. Exp. Meta. 13: 134–140.

  • Roth MG and Sternweis PC. . 1997 Curr. Opin. Cell. Biol. 9: 519–526.

  • Saksela O. . 1981 Anal. Biochem. 111: 276–282.

  • Sato H, Kita M and Seiki M. . 1993 J. Biol. Chem. 268: 23460–23468.

  • Silberman S, Janulis M and Schultz RM. . 1997 J. Biol. Chem. 272: 5927–5935.

  • Song J, Pfeffer LM and Foster DA. . 1991 Mol. Cell. Biol. 11: 4903–4908.

  • Urano T, Emkey R and Feig LA. . 1996 EMBO J. 15: 810–816.

  • Werb Z, Ashkenas J, MacAuley A and Wiesen JF. . 1996 Braz. J. Med. Biol. Res. 29: 1087–1097.

  • Williger B-T, Ho W-T and Exton JH. . 1999 J. Biol. Chem. 274: 735–738.

  • Yu H and Schultz RM. . 1990 Cancer Res. 50: 7623–7633.

  • Yu W, Kim J and Ossowski L. . 1997 J. Cell. Biol. 137: 767–777.

Download references

Acknowledgements

This work was supported by grants from the University of Buenos Aires (UBACYT ME074) and CONICET, PICT-0015-(BID 802/OC-AR) (to EB De Kier Joffe) and by grants from the National Institutes of Health (CA46677), the American Cancer Society (BE-243) (to DA Foster), and a Research Centers in Minority Institutions (RCMI) award from the Division of Research Resources, National Institutes of Health (RR-03037) to Hunter College. We thank Phil Kaplan and Liliana Ossowski for comments on the manuscript. We are particularly grateful to Alicia Rivelli for technical assistance.

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Aguirre-Ghiso, J., Frankel, P., Farias, E. et al. RalA requirement for v-Src- and v-Ras-induced tumorigenicity and overproduction of urokinase-type plasminogen activator: involvement of metalloproteases. Oncogene 18, 4718–4725 (1999). https://doi.org/10.1038/sj.onc.1202850

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1202850

Keywords

This article is cited by

Search

Quick links